14. 慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー Disease details / Clinical trials / Drug dev / DR info

: immunoglobulina umana normale per somministrazione endovenosa   
   LFB BIOTECHNOLOGIES
      2015   Phase 3   EUCTR2013-005558-31-IT   France;Germany;Italy;Mexico;Morocco;Spain;Turkey;United Kingdom;
ARGX-113   
   ARGENX BV
      2020   Phase 2   EUCTR2019-003107-35-IT   Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
   argenx BVBA
      2020   Phase 2   EUCTR2019-003107-35-PL   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003107-35-NL   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003107-35-HU   Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003107-35-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-PL   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-NL   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-ES   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-DK   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-CZ   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-BG   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
ARGX-117   
   argenx
      2022   Phase 2   NCT05225675   United States;
ARGX-117 IV   
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
   argenx BV
      2022   Phase 2   EUCTR2021-003302-50-NL   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2022   Phase 2   EUCTR2021-003302-50-ES   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Albumin (Human) , United States Pharmacopeia (USP)   
   Grifols Therapeutics Inc.
      2004   Phase 3   NCT00220740   Argentina;Canada;Czech Republic;Former Serbia and Montenegro;Germany;Israel;Italy;Mexico;Poland;Serbia;United States;
Anti-C5 antibody   
   Greater Glasgow and Clyde NHS Board and The University Of Glasgow
      2009   -   EUCTR2008-005748-18-GB   United Kingdom;
Anti-Thymocyte Globulin   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
Autologous Hematopoietic Stem Cell Transplantation   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
BIVV020   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 2   EUCTR2020-004006-54-IT   Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain;United Kingdom;United States;
   Sanofi-Aventis Recherche & Développement
      2021   Phase 2   EUCTR2020-004006-54-NL   France;Germany;Italy;Netherlands;Poland;
      2021   Phase 2   EUCTR2020-004006-54-FR   France;Netherlands;
      2021   Phase 2   EUCTR2020-004006-54-DE   France;Germany;Italy;Netherlands;Poland;
BIVV020/SAR445088   
   Bioverativ, a Sanofi company
      2021   Phase 2   NCT04658472   Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain;United States;
Carmustine   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
Cyclophosphamide   
   Stony Brook University
      2003   Phase 2   NCT01236456   United States;
Cytarabine   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
Dexamethasone   
   AMC Medical research BV
      2006   -   EUCTR2004-002783-24-GB   United Kingdom;
Eculizumab   
   Greater Glasgow and Clyde NHS Board and The University Of Glasgow
      2009   -   EUCTR2008-005748-18-GB   United Kingdom;
Efgartigimod PH20 SC   
   ARGENX BV
      2020   Phase 2   EUCTR2019-003107-35-IT   Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
   argenx
      2020   Phase 2   NCT04280718   Austria;Belgium;Bulgaria;China;Czechia;Denmark;France;Georgia;Germany;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
   argenx BVBA
      2021   Phase 2   EUCTR2019-003107-35-CZ   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2019-003076-39-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003107-35-PL   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003107-35-NL   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003107-35-HU   Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003107-35-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003107-35-DK   Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003107-35-DE   Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003107-35-BG   Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003107-35-BE   Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-PL   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-NL   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-ES   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-DK   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-DE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-CZ   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-BG   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-BE   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Efgartigimod PH20 SC in stage B   
   argenx
      2020   Phase 2   NCT04281472   Austria;Belgium;Bulgaria;China;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Efgartigimod alfa   
   ARGENX BV
      2020   Phase 2   EUCTR2019-003107-35-IT   Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
   argenx BVBA
      2020   Phase 2   EUCTR2019-003107-35-PL   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003107-35-NL   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003107-35-HU   Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003107-35-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-NL   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-ES   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003076-39-CZ   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Etoposide   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
FINGOLIMOD HYDROCHLORIDE   
   NOVARTIS PHARMA AG
      2012   Phase 3   EUCTR2011-005280-24-IT   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
   Novartis Pharma Services AG
      2015   Phase 2;Phase 3   EUCTR2011-005280-24-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Serbia;Spain;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2011-005280-24-PL   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2011-005280-24-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-GR   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
FTY720   
   Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K.
      2012   Phase 3   JPRN-JapicCTI-121961   -
FTY720I   
   NOVARTIS PHARMA AG
      2012   Phase 3   EUCTR2011-005280-24-IT   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
   Novartis Pharma Services AG
      2015   Phase 2;Phase 3   EUCTR2011-005280-24-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Serbia;Spain;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2011-005280-24-PL   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2011-005280-24-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-GR   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
Fampyra   
   Department of Neurology, Odense University Hospital
      2020   Phase 2   EUCTR2020-002438-34-DK   Denmark;
Fibrinogen concentrate   
   University Medical Centre Ljubljana
      2018   -   NCT03801135   Slovenia;
Fingolimod   
   Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K.
      2012   Phase 3   JPRN-JapicCTI-121961   -
Freeze-Dried Sulfonated Human Normal Immunoglobulin (GGS)   
   Teijin Pharma Limited
      2014   Phase 3   JPRN-JapicCTI-142472   Japan;
      2014   Phase 3   JPRN-JapicCTI-142471   Japan;
GILENYA 0,5 mg cápsulas duras   
   Novartis Pharma Services AG
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
Gammanorm   
   Aarhus Unversity Hospital
      2017   Phase 4   EUCTR2017-002024-24-DK   Denmark;
Gilenya   
   Novartis Pharma Services AG
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-GR   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
Group C meningococcal conjugate vaccine   
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
H.P. Acthar® Gel   
   Mamatha Pasnoor, MD
      2015   Phase 2   NCT02574962   United States;
HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE)   
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
HIDROCLORURO DE FINGOLIMOD   
   Novartis Pharma Services AG
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
HUMAN NORMAL IMMUNOGLOBULIN (IV)   
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
   Baxter Innovations GmbH
      2009   -   EUCTR2009-013841-27-DK   Denmark;
   CSL Behring GmbH
      2010   Phase 3   EUCTR2009-017672-24-BE   Belgium;Finland;
      2010   -   EUCTR2009-017672-24-FI   Finland;
   LFB BIOTECHNOLOGIES
      2016   Phase 3   EUCTR2013-005558-31-DE   France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
      2016   Phase 3   EUCTR2013-005557-73-DE   France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
      2015   Phase 3   EUCTR2013-005558-31-GB   France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
      2015   Phase 3   EUCTR2013-005558-31-FR   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
      2015   Phase 3   EUCTR2013-005558-31-ES   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
      2015   Phase 3   EUCTR2012-001995-12-IT   France;Italy;Spain;United Kingdom;
      2014   Phase 3   EUCTR2013-005557-73-IT   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
      2014   Phase 3   EUCTR2013-005557-73-GB   France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
      2014   Phase 3   EUCTR2013-005557-73-FR   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
      2014   Phase 3   EUCTR2013-005557-73-ES   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
      2013   Phase 3   EUCTR2012-001995-12-GB   France;Italy;Spain;United Kingdom;
      2013   Phase 3   EUCTR2012-001995-12-FR   France;Spain;United Kingdom;
      2013   Phase 3   EUCTR2012-001995-12-ES   France;Spain;United Kingdom;
Haemophilus type b vaccine (conjugated)   
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Hematopoietic stem cell transplantation   
   Northwestern University
      2005   Phase 2   NCT00278629   United States;
Hizentra   
   Aarhus University Hospital
      2019   Phase 4   EUCTR2018-003592-34-DK   Denmark;
      2013   Phase 2   EUCTR2013-001428-20-DK   Denmark;
   Aarhus Unversity Hospital
      2017   Phase 4   EUCTR2017-002024-24-DK   Denmark;
   CSL Behring
      2022   -   NCT04672733   France;
Hizentra®   
   CSL BEHRING GMBH
      2012   Phase 3   EUCTR2011-003448-28-IT   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;Germany;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
   CSL Behring GmbH
      2015   Phase 3   EUCTR2013-004157-24-CZ   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
      2015   Phase 3   EUCTR2011-003448-28-PL   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2011-003448-28-EE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   -   EUCTR2011-003448-28-LT   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004157-24-NL   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
      2014   Phase 3   EUCTR2013-004157-24-IT   Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
      2014   Phase 3   EUCTR2013-004157-24-GB   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004157-24-FI   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
      2014   Phase 3   EUCTR2013-004157-24-ES   Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
      2014   Phase 3   EUCTR2013-004157-24-DE   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
      2012   Phase 3   EUCTR2011-003448-28-NL   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-GB   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-FI   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-ES   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-DE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-BE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   -   EUCTR2011-003448-28-AT   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States;
Human normal immunoglobulin (IVIg)   
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Human normal immunoglobulin (SCIg)   
   CSL Behring GmbH
      2015   Phase 3   EUCTR2013-004157-24-CZ   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
      2015   Phase 3   EUCTR2011-003448-28-PL   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2011-003448-28-EE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   -   EUCTR2011-003448-28-LT   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004157-24-NL   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
      2014   Phase 3   EUCTR2013-004157-24-IT   Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
      2014   Phase 3   EUCTR2013-004157-24-GB   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004157-24-FI   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
      2014   Phase 3   EUCTR2013-004157-24-ES   Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
      2014   Phase 3   EUCTR2013-004157-24-DE   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
      2012   Phase 3   EUCTR2011-003448-28-NL   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-GB   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-FI   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-ES   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-DE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-BE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   -   EUCTR2011-003448-28-AT   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States;
Human normal immunoglobulin G (IgG > purity)   
   CSL Behring GmbH
      2010   Phase 3   EUCTR2009-017672-24-BE   Belgium;Finland;
      2010   -   EUCTR2009-017672-24-FI   Finland;
Human normal immunoglobulin for intravenous administration   
   LFB BIOTECHNOLOGIES
      2016   Phase 3   EUCTR2013-005557-73-DE   France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
      2015   Phase 3   EUCTR2013-005558-31-GB   France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
      2015   Phase 3   EUCTR2012-001995-12-IT   France;Italy;Spain;United Kingdom;
      2014   Phase 3   EUCTR2013-005557-73-IT   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
      2014   Phase 3   EUCTR2013-005557-73-GB   France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
      2014   Phase 3   EUCTR2013-005557-73-FR   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
      2014   Phase 3   EUCTR2013-005557-73-ES   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
      2013   Phase 3   EUCTR2012-001995-12-GB   France;Italy;Spain;United Kingdom;
      2013   Phase 3   EUCTR2012-001995-12-FR   France;Spain;United Kingdom;
      2013   Phase 3   EUCTR2012-001995-12-ES   France;Spain;United Kingdom;
Human normal immunoglobulin for intravenous administrationn   
   LFB BIOTECHNOLOGIES
      2016   Phase 3   EUCTR2013-005558-31-DE   France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
      2015   Phase 3   EUCTR2013-005558-31-FR   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
      2015   Phase 3   EUCTR2013-005558-31-ES   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
Hyqvia   
   UMC Utrecht
      2016   Phase 3   EUCTR2015-000828-28-NL   Netherlands;
I10   
   LFB BIOTECHNOLOGIES
      2016   Phase 3   EUCTR2013-005558-31-DE   France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
      2016   Phase 3   EUCTR2013-005557-73-DE   France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
      2015   Phase 3   EUCTR2013-005558-31-GB   France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
I10E   
   LFB BIOTECHNOLOGIES
      2015   Phase 3   EUCTR2013-005558-31-IT   France;Germany;Italy;Mexico;Morocco;Spain;Turkey;United Kingdom;
      2015   Phase 3   EUCTR2013-005558-31-FR   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
      2015   Phase 3   EUCTR2013-005558-31-ES   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
      2015   Phase 3   EUCTR2012-001995-12-IT   France;Italy;Spain;United Kingdom;
      2014   Phase 3   EUCTR2013-005557-73-IT   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
      2014   Phase 3   EUCTR2013-005557-73-GB   France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
      2014   Phase 3   EUCTR2013-005557-73-FR   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
      2014   Phase 3   EUCTR2013-005557-73-ES   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
      2013   Phase 3   EUCTR2012-001995-12-GB   France;Italy;Spain;United Kingdom;
      2013   Phase 3   EUCTR2012-001995-12-FR   France;Spain;United Kingdom;
      2013   Phase 3   EUCTR2012-001995-12-ES   France;Spain;United Kingdom;
I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)   
   Laboratoire français de Fractionnement et de Biotechnologies
      2013   Phase 3   NCT01951924   France;Italy;Spain;United Kingdom;
IGIV,   
   Baxter Innovations GmbH
      2009   -   EUCTR2009-013841-27-DK   Denmark;
IGVENA*FL 200ML 10G+SET   
   KEDRION
      2007   -   EUCTR2005-001136-76-IT   Italy;
IMMUNOGLOBULIN G   
   CSL Behring AG
      2008   Phase 2   EUCTR2007-000710-37-GB   Germany;Italy;United Kingdom;
      2007   -   EUCTR2007-000710-37-DE   Germany;Italy;United Kingdom;
IQYMUNE   
   LFB BIOTECHNOLOGIES
      2016   Phase 3   EUCTR2013-005558-31-DE   France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
      2016   Phase 3   EUCTR2013-005557-73-DE   France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
      2015   Phase 3   EUCTR2013-005558-31-GB   France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
      2014   Phase 3   EUCTR2013-005557-73-GB   France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
IgPro10   
   CSL Behring
      2019   Phase 4   NCT03684018   Canada;United States;
      2012   Phase 3   NCT01545076   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
IgPro20   
   CSL Behring
      2014   Phase 3   NCT02027701   Australia;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
   CSL Behring GmbH
      2015   Phase 3   EUCTR2013-004157-24-CZ   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
      2015   Phase 3   EUCTR2011-003448-28-PL   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2011-003448-28-EE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   -   EUCTR2011-003448-28-LT   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004157-24-NL   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
      2014   Phase 3   EUCTR2013-004157-24-IT   Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
      2014   Phase 3   EUCTR2013-004157-24-GB   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004157-24-FI   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
      2014   Phase 3   EUCTR2013-004157-24-ES   Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
      2014   Phase 3   EUCTR2013-004157-24-DE   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
      2012   Phase 3   EUCTR2011-003448-28-NL   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-GB   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-FI   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-ES   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-DE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-003448-28-BE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2012   -   EUCTR2011-003448-28-AT   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States;
IgPro20 (high dose)   
   CSL Behring
      2012   Phase 3   NCT01545076   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
IgPro20 (low dose)   
   CSL Behring
      2012   Phase 3   NCT01545076   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
Immune Globulin IV (Human), Caprylate/Chromatography Purified   
   Grifols Therapeutics Inc.
      2004   Phase 3   NCT00220740   Argentina;Canada;Czech Republic;Former Serbia and Montenegro;Germany;Israel;Italy;Mexico;Poland;Serbia;United States;
Immune Globulin Intravenous (human),   
   Baxalta now part of Shire
      2008   Phase 3   NCT00666263   Canada;Denmark;Netherlands;Poland;United States;
Immune Globulin Intravenous Solution   
   Vera Bril
      2017   Phase 3   NCT03166527   Canada;
Immune Globulin Subcutaneous (Human)   
   University of South Florida
      2014   -   NCT02465359   United States;
Immune globulin   
   National Center for Research Resources (NCRR)
      1992   Phase 3   NCT00004772   -
Immunoadsorption   
   University of Ulm
      2022   Phase 2   NCT04881682   Germany;
Immunoglobulin   
   University of Aarhus
      2020   Phase 4   NCT04589299   Denmark;
Immunoglobulin perfusion   
   Centre Hospitalier Universitaire de Saint Etienne
      2004   Phase 3   NCT01349270   France;
Immunoglobuline G   
   Octapharma AG
      2011   Phase 2;Phase 3   EUCTR2009-017805-13-CZ   Bulgaria;Czech Republic;
      2011   -   EUCTR2009-017805-13-BG   Bulgaria;Czech Republic;India;Mexico;Poland;Romania;Serbia;Ukraine;
      2010   Phase 2;Phase 3   EUCTR2009-017805-13-RO   Bulgaria;Czech Republic;Romania;
Immunoglobulins   
   Rigshospitalet, Denmark
      2014   -   NCT02111590   Denmark;
   University of Ulm
      2022   Phase 2   NCT04881682   Germany;
Immunoglobulins, normal human, for extravascular adm.   
   CSL Behring AG
      2007   -   EUCTR2007-000710-37-IT   Germany;Italy;United Kingdom;
Immunoglobulins, normal human, for intravascular adm.   
   KEDRION
      2007   -   EUCTR2005-001136-76-IT   Italy;
Intratect   
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Intravenous Immunoglobulin   
   University of Minnesota
      2015   -   NCT02414490   United States;
Intravenous immunoglobulin   
   University of Aarhus
      2005   Phase 2   NCT00268788   Denmark;
Intravenous immunoglobulin (IVIg)   
   National Institute of Neurological Disorders and Stroke (NINDS)
      1990   Phase 2   NCT00001287   United States;
J07AH07   
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
KIOVIG   
   LFB BIOTECHNOLOGIES
      2015   Phase 3   EUCTR2012-001995-12-IT   France;Italy;Spain;United Kingdom;
      2013   Phase 3   EUCTR2012-001995-12-GB   France;Italy;Spain;United Kingdom;
      2013   Phase 3   EUCTR2012-001995-12-FR   France;Spain;United Kingdom;
      2013   Phase 3   EUCTR2012-001995-12-ES   France;Spain;United Kingdom;
KIOVIG 100 mg/ml solution for infusion   
   Baxter Innovations GmbH
      2009   -   EUCTR2009-013841-27-DK   Denmark;
Kiovig   
   Erasmus MC
      2014   Phase 4   EUCTR2013-004988-32-NL   Netherlands;
Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)   
   Laboratoire français de Fractionnement et de Biotechnologies
      2013   Phase 3   NCT01951924   France;Italy;Spain;United Kingdom;
Lipoic acid   
   Oregon Health and Science University
      2009   Phase 2   NCT00962429   United States;
MABTHERA - 1 FIALA 500 MG 50 ML   
   IRCCS ISTITUTO CLINICO HUMANITAS
      2018   Phase 3   EUCTR2017-005034-36-IT   Italy;
      2018   Phase 2   EUCTR2018-001347-31-IT   Italy;
MD1003   
   MedDay Pharmaceuticals SA
      2016   Phase 2   NCT02967679   France;
Melphalan   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
Menjugate   
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Methylprednisolon (Solu-Medrol)   
   Academisch Medisch Centrum
      2018   Phase 3   EUCTR2017-002511-34-NL   Netherlands;
Methylprednisolone   
   Academic Medical Centre, Amsterdam, NL
      2019   Phase 3   EUCTR2017-002511-34-GB   Netherlands;United Kingdom;
Methylprednisolone (Solu-Medrol)   
   Academisch Medisch Centrum
      2018   Phase 3   EUCTR2017-002511-34-NL   Netherlands;
N. MENINGITIDIS GROUP C POLYSACCHARIDE   
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
NPB-01   
   Nihon Pharmaceutical Co., Ltd
      2013   Phase 3   NCT01827072   Japan;
      2013   Phase 3   NCT01824251   Japan;
NewGam   
   Octapharma
      2017   Phase 3   NCT02638207   Australia;Bulgaria;Canada;Czechia;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
   Octapharma AG
      2011   Phase 2;Phase 3   EUCTR2009-017805-13-CZ   Bulgaria;Czech Republic;
      2011   -   EUCTR2009-017805-13-BG   Bulgaria;Czech Republic;India;Mexico;Poland;Romania;Serbia;Ukraine;
      2010   Phase 2;Phase 3   EUCTR2009-017805-13-RO   Bulgaria;Czech Republic;Romania;
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2017   Phase 3   EUCTR2015-005443-14-SE   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
      2017   Phase 3   EUCTR2015-005443-14-PL   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
      2017   Phase 3   EUCTR2015-005443-14-HU   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
      2017   Phase 3   EUCTR2015-005443-14-DK   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
      2017   Phase 3   EUCTR2015-005443-14-DE   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
      2017   Phase 3   EUCTR2015-005443-14-CZ   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
      2017   Phase 3   EUCTR2015-005443-14-BG   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
PANZYGA   
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2017   Phase 3   EUCTR2015-005443-14-SE   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
      2017   Phase 3   EUCTR2015-005443-14-PL   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
      2017   Phase 3   EUCTR2015-005443-14-HU   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
      2017   Phase 3   EUCTR2015-005443-14-DK   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
      2017   Phase 3   EUCTR2015-005443-14-DE   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
      2017   Phase 3   EUCTR2015-005443-14-CZ   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
      2017   Phase 3   EUCTR2015-005443-14-BG   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
Panzyga   
   Octapharma
      2022   Phase 3   NCT04929236   -
Peripheral Blood Stem Cell Transplantation   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
Placebo   
   Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K.
      2012   Phase 3   JPRN-JapicCTI-121961   -
Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)   
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Prednisolone   
   AMC Medical research BV
      2006   -   EUCTR2004-002783-24-GB   United Kingdom;
Prednisone   
   Centre Hospitalier Universitaire de Saint Etienne
      2004   Phase 3   NCT01349270   France;
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
Prevenar 13 sospensione per iniezione   
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Privigen   
   Aarhus University Hospital
      2019   Phase 4   EUCTR2018-003592-34-DK   Denmark;
      2013   Phase 2   EUCTR2013-001428-20-DK   Denmark;
Privigen®   
   CSL Behring GmbH
      2010   Phase 3   EUCTR2009-017672-24-BE   Belgium;Finland;
      2010   -   EUCTR2009-017672-24-FI   Finland;
RHuPH20   
   UMC Utrecht
      2016   -   NCT02885259   Netherlands;
RVG 51680   
   Department of Neurology, Academic Medical Center
      2014   -   EUCTR2013-005363-52-NL   Netherlands;
RVG 56083   
   Academisch Medisch Centrum
      2018   Phase 3   EUCTR2017-002511-34-NL   Netherlands;
Recombinant human hyaluronidase   
   Nishizawa Atsushi
      2021   Phase 3   JPRN-jRCT2051210110   Japan;
Rituximab   
   Iijima Masahiro
      2021   Phase 2   JPRN-jRCTs041210046   Japan;
      2019   Phase 2   JPRN-jRCT2041180037   Japan;
   Nagoya University Hospital
      2019   Phase 2   JPRN-UMIN000035753   Japan;
   University of Kansas Medical Center
      2022   Phase 2   NCT04480450   -
Rituximab (genetical recombination)   
   Nagoya University
      2019   Phase 2   NCT03864185   Japan;
Rozanolixizumab   
   UCB Biopharma S.P.R.L.
      2019   Phase 2   NCT03861481   Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
   UCB Biopharma SRL
      2020   -   NCT05014724   -
      2019   Phase 2   NCT04051944   Belgium;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
SAR445088 (formerly BIVV020)   
   Sanofi-Aventis Recherche & Développement
      2021   Phase 2   EUCTR2020-004006-54-PL   France;Germany;Italy;Netherlands;Poland;
SOLU MEDROL - 125 MG/2 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 125 MG/2 ML   
   IRCCS ISTITUTO CLINICO HUMANITAS
      2018   Phase 3   EUCTR2017-005034-36-IT   Italy;
Sodium chloride   
   Academic Medical Centre, Amsterdam, NL
      2019   Phase 3   EUCTR2017-002511-34-GB   Netherlands;United Kingdom;
Subcutaneous immunoglobulin   
   University of Aarhus
      2005   Phase 2   NCT00268788   Denmark;
Subcuvia   
   Aarhus Unversity Hospital
      2017   Phase 4   EUCTR2017-002024-24-DK   Denmark;
   Johannes Jakobsen
      2016   Phase 2   NCT02556437   Denmark;
   Rigshospitalet
      2015   Phase 2   EUCTR2015-003453-18-DK   Denmark;
Syngeneic Bone Marrow Transplantation   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
TACHIPIRINA - 1000 MG COMPRESSE 8 COMPRESSE   
   IRCCS ISTITUTO CLINICO HUMANITAS
      2018   Phase 3   EUCTR2017-005034-36-IT   Italy;
TAK-771   
   Takeda
      2021   Phase 3   NCT05084053   Japan;
TRIMETON - 10 MG/1 ML SOLUZIONE INIETTABILE 5 FIALE 1 ML   
   IRCCS ISTITUTO CLINICO HUMANITAS
      2018   Phase 3   EUCTR2017-005034-36-IT   Italy;
UCB7665   
   UCB Biopharma SPRL
      2020   Phase 2   EUCTR2018-004392-12-NL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-004392-12-DE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004392-12-GB   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004392-12-FR   Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004392-12-ES   Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004392-12-DK   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2016-002411-17-NL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2016-002411-17-GB   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2016-002411-17-FR   Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2016-002411-17-ES   Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2016-002411-17-DK   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2016-002411-17-DE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
   UCB Biopharma SRL
      2019   Phase 2   EUCTR2018-004392-12-BE   Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2016-002411-17-BE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
VACCINO PNEUMOCOCCICO SACCARIDICO   
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Vivaglobin   
   CSL Behring
      2007   Phase 2   NCT00701662   Germany;Italy;Switzerland;United Kingdom;
   CSL Behring AG
      2008   Phase 2   EUCTR2007-000710-37-GB   Germany;Italy;United Kingdom;
      2007   -   EUCTR2007-000710-37-IT   Germany;Italy;United Kingdom;
      2007   -   EUCTR2007-000710-37-DE   Germany;Italy;United Kingdom;
intravenous immunoglobulin (IVIg)   
   University of Toronto
      2015   Phase 4   NCT02372149   Canada;
liquid formulation of human immunoglobulin   
   CSL Behring
      2010   Phase 3   NCT01184846   Belgium;Finland;France;Germany;Poland;